Calcium-channel blockers for prophylaxis of radiocontrast-associated nephrotoxicity.
Because of both an absence of sufficient data and the concern for increased toxicity in certain patient populations, the use of CCBs to reduce radiocontrast-associated nephrotoxicity is not recommended. Additional prospective, randomized trials are needed.